STING1 and cancer: Manipulating the immune composition of the TME of CIN+ cancers, exploiting CIN-dependent metabolic vulnerabilities, manipulating CIN rates, modulating of the ECM, and exploiting the multifaceted role of STING signalling all emerge as promising strategies to battle CIN+ cancers (Figure 2).